Last reviewed · How we verify
EGT0001442
EGT0001442's mechanism of action is currently unknown.
At a glance
| Generic name | EGT0001442 |
|---|---|
| Also known as | Bexagliflozin, Human SGLT2 inhibitor |
| Sponsor | Theracos |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
There is limited information available on EGT0001442's mechanism of action, and it is not well understood at this time.
Approved indications
Common side effects
Key clinical trials
- An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension (PHASE2, PHASE3)
- Bexagliflozin Drug/Drug Interaction Study With Digoxin (PHASE1)
- Bexagliflozin Efficacy and Safety Trial (PHASE3)
- Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
- Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects (PHASE1)
- Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus (PHASE2)
- Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment (PHASE3)
- A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EGT0001442 CI brief — competitive landscape report
- EGT0001442 updates RSS · CI watch RSS
- Theracos portfolio CI